Home
Contact
Publications
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
16th June 2017
Nitin Jain
Enadenotucirev Preclinical
Click here for Full Text
Share this Story
Facebook
Twitter
LinkedIn
Reddit
Digg
Delicious
Google++
E-Mail+
About the Author
Comments are closed.
Prev Post
Next Post
Filter Publications
Enadenotucirev Preclinical
Enadenotucirev Clinical
T-SIGn
Reviews
See All Publications
© Copyright 2021 PsiOxus Therapeutics
RSS
Back to Top
About
Vision & Strategy
Our People
T-SIGn Platform Technology
Pipeline
Publications and Posters
Partners and Investors
News and Events
Careers
Contact Us
Menu
Comments are closed.